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Abstract  
Aims: Our current understanding of the pathogenesis of type 1 diabetes (T1D) arose in large part 
from studies using the non-obese diabetic (NOD) mouse model. In the present study, we chose a 
human-focused method to investigate T1D disease mechanisms and potential targets for 
therapeutic intervention by directly analyzing human donor pancreatic islets from individuals 
with T1D.  
Materials and Methods: We obtained islets from a young individual with T1D for three years 
and an older individual with T1D for 27 years and performed unbiased functional genomic 
analysis by high-depth RNA sequencing; the T1D islets were compared with islets isolated from 
three non-diabetic donors.  
Results: The islets procured from these T1D donors represent a unique opportunity to identify 
gene expression changes in islets after significantly different disease duration. Data analysis 
identified several inflammatory pathways upregulated in short-duration disease, which notably 
included many components of innate immunity. As proof of concept for translation, one of the 
pathways, governed by IL-23(p19), was selected for further study in NOD mice because of 
ongoing human trials of biologics against this target for different indications. A mouse 
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monoclonal antibody directed against IL-23(p19) when administered to NOD mice resulted in a 
significant reduction in diabetes incidence. 
Conclusion: While sample size for this study is small, our data demonstrates that the direct 
analysis of human islets provides a greater understanding of human disease. These data, together 
with the analysis of an expanded cohort to be obtained by future collaborative efforts, might 
result in the identification of promising novel targets for translation into effective therapeutic 
interventions for human T1D, with the added benefit to repurpose known biologicals for use in 
different indications. 
 
Introduction 
Type 1 diabetes (T1D) is an autoimmune disorder in which autoreactive T cells target and 
destroy pancreatic insulin-producing beta cells. This is probably preceded by local inflammation 
and activation of the innate immune response 1. Much of our current understanding of T1D 
pathogenesis arose from studies in non-obese diabetic (NOD) mice 2. Studies performed in 
animal models do provide researchers with the ability to manipulate the genetics and physiology 
of a mammalian system, thereby providing valuable information regarding disease pathogenesis 
and progression. That said, interventions based on pathways identified to be specifically altered 
in NOD mice 3,4 have up to now failed in translation to human disease, leading at best to partial 
stabilization of the insulin secretory capacity of beta cells for short periods of time 5,6. 
Additionally, insulitis is not a uniform pathological feature of the pancreas in human T1D 7 as it 
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is in NOD mice, and the presence of beta cell mass is evident in many individuals years after 
onset 8. Therefore, the direct study of human T1D at various stages of progression may better 
identify targets that reduce progression or reverse disease. The subsequent manipulation or 
validation of these targets in mouse models would then provide additional support for moving a 
candidate toward human clinical study.  
 There has been increasing evidence recently that beta cells may not be simply bystanders 
in an autoimmune process, but rather active players in the progression and pathophysiology of 
disease 9–11. This suggests that an in-depth molecular analysis of human islets from individuals 
with T1D compared with healthy controls could provide insight into new therapeutic approaches. 
Here, we present a proof of concept study wherein RNA deep sequencing data from the islets of 
two individuals with different T1D disease duration were analyzed to parse the changes in gene 
expression pathways after three years of disease (hereafter referred to as “short-duration”) 
compared with 27 years of disease (hereafter referred to as “long-duration”) as compared to no 
disease (non-diabetic control donors). Our data suggest that disease duration impacts the nature 
of inflammatory pathways activated, and at least one pathway (Th1/Th17) displays the potential 
to be exploited in both humans and NOD mice for the prevention or possible remission of 
diabetes.  
 
Materials and Methods 
Human Islets 
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Human islets were obtained from deceased organ donors through the Integrated Islet 
Distribution Program and Vanderbilt University (https://iidp.coh.org/Centers/Policies-Standard-
Operating-Procedures). Supplemental Tables 1 and 2 outline donor characteristics. Islet 
isolations from young donors or donors with long-standing T1D are not a common occurrence 
and therefore represent an opportunity to analyze unique aspects of the disease. T1D islets were 
recovered with good viability (87% and 92%, respectively) and purity (~ 80%); islets recovered 
from three non-diabetic control donors also showed good viability (95 – 96%) and purity (80 – 
90%). Shipments of islets were received at the Indiana University School of Medicine (IUSM) 
and placed into human islet media, which included standard islet media (Prodo Laboratories), 
human AB serum supplement (Prodo Laboratories), glutamine and glutathione supplement 
(Prodo Laboratories) and ciprofloxacin (Fisher). All islets were hand-picked to exclude non-islet 
material and increase purity. RNA was extracted from 200- 600 islets using the RNeasy Mini 
Extraction kit (Qiagen) and equivalent concentrations of RNA from each sample were used for 
RNA sequencing experiments.  
 
RNA Sequencing 
High-depth RNA sequencing was performed using an Illumina HISeq3000 (Indiana University; 
https://cgb.indiana.edu/sequencing/index.html), with approximately 239 million paired-end reads 
obtained per sample. Reads were mapped to the human reference genome GRCh37/hg19 using 
Tophat 2 12,13 and Gencode version 18 annotation dataset 14,15. Mapped reads were used to 
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quantify gene abundance using the FluxCapacitor program version 1.6.1 16. All genes were 
assigned a relative expression level measured in RPKM units (‘reads per kilobase per million 
mapped reads’) 17. The two islet samples from T1D donors were analyzed and compared 
separately with control islets. Genes with expression of RPKM > 0.5 in at least one of the 
samples studied and with potential pathogenic relevance were identified and reported in Results. 
To define a gene as up- or down-regulated, a cut-off was used of a three-fold change (FC) 
compared to the control median expression value. The association of up- or down-regulated 
genes with molecular/cellular functions and pathways was performed using Ingenuity Pathway 
Analysis (IPA; Ingenuity Systems). Raw data was deposited in the Gene Expression Omnibus 
(GEO) database (GSE102371) and on the IBRI website (http://data.indianabiosciences.org). 
Gene expression patterns from all T1D and control donor islets were also compared with RNA 
sequencing data from cytokine-treated human islets (unpublished dataset and 18) as well as other 
human tissues from the Illumina bodyMap2 transcriptome project available in GEO 
(GSE30611). 
 
Immunofluorescence 
 Pancreatic tissue sections from paraffin-embedded blocks were obtained from the 
individuals with short-duration T1D, long-duration T1D, and one non-diabetic control. 
Immunofluorescent staining was performed as previously published 19. Primary antibodies used 
include guinea pig anti-insulin (1:1000; Thermo), mouse anti-glucagon (1:500; Abcam), mouse 
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anti-CD66b conjugated with DyLight 550 (1:200; clone G10F5; Novus), rabbit anti-amylase 
(1:500; Sigma). For all non-conjugated primary antibodies, Alexa-488, Cy3, and Alexa-647 
secondary antibodies (1:500; Jackson ImmunoResearch) were then used. DAPI (Sigma) was 
used to visualize nuclei. Images were acquired with a Zeiss 710 confocal microscope. 
 
Drug studies in NOD mice 
 Female NOD mice were obtained from Jackson Laboratories (Bar Harbor, ME) at 5 
weeks of age and acclimated for 1 week prior to experimentation. All animal studies were 
approved by the Institutional Animal Care and Use Committee at IUSM. Anti-IL-23(p19) 
(CNTO6163) and mouse IgG isotype control (CNTO1322) were provided by Jansen Research 
and Development, LLC. Drugs were administered by intraperitoneal injection to animals at 6 
weeks of age. To determine treatment outcome, blood was drawn weekly to assess glycemic 
control. Diabetes was defined as blood glucose >250 mg/dL on three separate occasions; after 
the first value >250 mg/dL, daily monitoring was performed. The treatment groups were: (1) 6-
week-old NOD mice treated weekly for 27 weeks with 0.5 mg/mouse CNTO6163 in PBS 
(N=24); (2) 6-week-old NOD mice treated weekly for 27 weeks with 0.5 mg/mouse CNTO1322 
in PBS (N=12). Pancreas tissue was collected for insulitis scoring, which was performed as 
described previously 20.  
 
Results  
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Differential gene expression in human islets from individuals with T1D 
Using RNA-sequencing, we characterized differential gene expression in islets isolated 
from two individuals with T1D of vastly different duration. The individual designated as short-
duration was 6 years old and had T1D for 3 years whereas the individual designated as long-
duration was 38 years old and had T1D for 27 years. For comparison, we profiled islets from 
three non-diabetic individuals, aged 11, 12, and 64 (Supplemental Tables 1 and 2). Gene 
expression patterns from all islet samples were compared with gene expression data from other 
human tissues collected as part of the Illumina bodyMap2 transcriptome project (Figure 1). 
Importantly, islet preparations clustered together but were separate from other tissues, indicating 
that even with diabetes the islets retained an “islet identity signature”. 
Short-duration T1D islets showed 667 upregulated and 2564 downregulated genes 
compared with controls. Similarly, comparing long-duration T1D with controls identified 660 
upregulated and 2539 downregulated genes. Despite a similar total number of genes 
differentially expressed in the islets of both T1D donors (3231 versus 3199 genes), the specific 
genes altered were not identical, with only 18.1% and 46.5% of the up- and down-regulated 
genes, respectively, overlapping between short- and long-duration T1D.  
 Expression values for a select group of genes are in Table 1. Of note, insulin (INS) 
expression is present in T1D islets, but at < 0.1% of control values. A reduction of insulin-
expressing cells was confirmed by immunofluorescence on tissue from these individuals; 
glucagon-expressing cells identified islet areas (Supplemental Figure 1). Importantly, this 
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immunofluorescence analysis was performed on sections from only one area of the pancreas and 
therefore can only provide a cellular view of the tissue from that area. The gene expression data 
gathered by RNA sequencing, on the other hand, provides a more complete picture of islet 
hormone gene expression across all obtained islets. Interestingly, in addition to the global 
reduction in insulin gene expression, the expression of all islet hormone genes, including 
glucagon (GCG), ghrelin (GHRL), somatostatin (SST), and pancreatic polypeptide (PPY), was 
reduced in both T1D samples compared with controls. Select transcription factors significant to 
beta cell function, such as MAFA, NEUROD1 and PDX1, also showed reduced expression (Table 
1). Together, these data confirm a reduction in insulin-expressing beta cells and a possible 
reduction in differentiated islets cells in both individuals with T1D. 
 
Pathways altered in T1D  
 To obtain an unbiased global view of the data, we identified pathways corresponding to 
collections of genes altered in short-duration or long-duration T1D compared with controls 
(Table 2; Supplemental Figure 2; Supplemental Tables 3-6). Based on the genes and pathways 
identified, the software also delineated potential upstream regulators of the up- and down-
regulated pathways (Supplemental Tables 7 and 8). Given the reduction in beta cells observed 
and quantitative loss of hormone gene expression, these downregulated pathways are likely 
influenced by altered islet composition.  
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Inflammatory genes up-regulated in islets early in disease 
 The scale of upregulation [log (B-H p value)] for pathways altered in short-duration T1D 
was particularly noteworthy and included marked expression of inflammatory-related pathways 
(Figure 2). “Granulocyte adhesion and diapedesis” was the top canonical pathway increased in 
short-duration T1D (Table 2). Additionally, several genes usually expressed in neutrophils, such 
as CXCL1, CXCL2, CXCL3, CXCL5, CXCL10, CXCL12, CCCL12, CCL3 and CCCL20, and 
the cytokines IL-1 and IL-8, showed much higher expression in short-duration T1D compared 
with controls (Table 1). These findings suggest there may exist a protracted infiltration into the 
islets by innate immune cells such as granulocytes or antigen presenting cells 
(monocytes/macrophages), along with local production of pro-inflammatory cytokines. To test 
this hypothesis we compared the present T1D islet gene expression findings against our previous 
findings with human islets exposed to the inflammatory cytokines IL-1beta and IFN-gamma 18. 
Interestingly, short-duration T1D islets showed a similarity of 36% up-regulated (240 mRNAs) 
and 37% down-regulated (956 mRNAs) genes compared with cytokine-treated islets; these 
values were lower in long-duration T1D, namely a similarity of 11% up-regulated (77 mRNAs) 
and 29% down-regulated (745 mRNAs) genes compared with cytokine-treated human islets. In 
line with this, pathway analysis identified TNF-alpha, IL-1beta, IFN-gamma and their 
downstream transcription factors NF-kB and STAT1 10, as key upstream regulators of the gene 
networks observed as up-regulated in short-duration T1D (Supplemental Table 7). On the other 
hand, the upstream regulators of the down-regulated genes were transcription factors related to 
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beta cell function (Supplemental Table 8), which is in line with the decrease in insulin expression 
and beta cells (Table 1; Supplemental Figure 1). 
 
Reduced progression to diabetes with early inhibition of IL-23/p19 in NOD mice  
 Given the number of inflammatory pathways altered with short-duration T1D, we asked 
if inhibiting one inflammatory pathway not previously implicated in T1D progression might alter 
diabetes outcome. Our data identified interleukin 23 alpha subunit p19 (IL23A) and two IL-17A 
pathways (downstream of IL-23) were increased in short-duration T1D, but not long-duration 
T1D (Table 1). This target also proved interesting given its current evaluation as a therapeutic for 
other human autoimmune-related indications, specifically Psoriasis, Crohn’s Disease, Plaque 
Psoriasis, and Ulcerative Colitis (NCT01947933, NCT02891226, NCT02899988, and 
NCT02589665). We therefore sought to inhibit IL-23(p19) in NOD mice early in the course of 
disease (6 weeks), corresponding to the early stages of insulitis (Figure 3A). NOD mice treated 
at 6 weeks of age with anti-IL-23(p19) were followed with weekly blood glucose measurements 
to determine diabetes onset. Interestingly, treated mice showed significantly reduced progression 
to diabetes compared with controls (Figure 3B; p = 0.034).  Moreover, anti-IL-23(p19) treatment 
decreased insulitis severity (Figure 3A). These data suggest that inhibition of inflammatory 
pathways identified by functional genomic analysis of human islets from individuals with T1D 
can alter the course of disease in NOD mice. 
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Discussion  
 Therapeutic interventions derived from pathways first identified to be altered in rodent 
disease have not effectively translated to interventions in human T1D. We postulate this is 
because targets are selected based on a disease pathophysiology specific to NOD mice, which 
may be different from that of the human disease. Therefore, we proposed the alternative concept 
of selecting targets for subsequent studies in animal models by first examining the relevant 
human tissue, in this case pancreatic islets from individuals with T1D. Thus, pancreatic islets 
from two individuals with T1D, where disease duration was vastly different, were analyzed. 
Specifically, we performed functional genomic analysis of islets from donors with short-duration 
disease (3 years) or long-duration disease (27 years). When compared to islets from non-diabetic 
donors, our analysis identified pathways that displayed distinctly different expression patterns 
between the islets of the two T1D donors and between the islets from the T1D donors and non-
diabetic controls. This identified, among others, a pathway governed by IL-23(p19), which was 
selected for further study in NOD mice. We recognize that there are caveats associated with the 
study of only two T1D donors. On the other hand, the treatment of NOD mice early in disease 
progression with an inhibitor for one of these altered human pathways resulted in a significant 
reduction in disease incidence. Therefore, we believe that the present study underscores the value 
of using human tissue as the primary point of interrogation, as well as the utility of mouse 
models to then manipulate these human disease-relevant pathways to support possible 
therapeutic translation. 
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 One of the most distinct differences observed in the data was the upregulation of innate 
immunity-related pathways in T1D islets, particularly in short-duration disease. This finding is in 
line with previously published histology from pancreata of individuals with T1D 21. Our data are 
also in line with flow cytometry analysis of islets from the same individual with short-duration 
T1D (nPOD69), which were subjected to a T cell stimulatory assay that confirmed the presence 
of CD45+ cells in the islets 22. Given previous reports that insulitis in human T1D is not uniform 
and challenging to observe 7,8, an additional interpretation of our data is that the islets themselves 
express certain genes, particularly chemokines, which influence the recruitment of inflammatory 
cells to the pancreas early in disease. Given the striking similarity in expression patterns 
observed in short-duration T1D, which showed more active inflammation, with previous findings 
in islets exposed to IL-1 beta and IFN-gamma 18, it is conceivable that these, or other cytokines 
signaling via similar pathways, are in the islet environment and relevant for early stage human 
disease pathogenesis. These observations are supported by previous studies that identified an 
“interferon signature” in islets from pancreas biopsies of patients soon after diabetes diagnosis 23.  
  Another significant finding was the increased IL23A in short-duration T1D. Th17-
expressing T cells may participate in human T1D progression 24–26. IL-23 augments Th17 cell 
development and interestingly, IL-23 shares the p40 subunit with IL-12 but pairs with a 19 kDa 
peptide (p19). Similar to IL-12, IL-23 is secreted by activated APCs. Early studies documenting 
the role of IL-12 in Th1-mediated disease manipulated the p40 subunit, which is shared between 
IL-12 and IL-23. Therefore, p40 manipulation likely impacted both Th1 and Th17 pathways. Our 
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identification of increased IL23A(p19) suggested that manipulating this factor, rather than p40, 
may be useful to dampen the upregulation of inflammatory pathways early in disease. 
Interestingly, an IL23A haplotype variant was identified to have a protective effect on T1D 27, 
which implicates a role for this target in autoimmune diabetes. Multiple active clinical trials 
evaluating Mirikizumab (NCT01947933, NCT02891226, NCT02899988, and NCT02589665), 
which targets IL23(p19), as a therapeutic for other autoimmune-related indications further 
supported the evaluation of this target in reducing the inflammatory response and therefore 
possibly T1D progression. Our treatment of NOD mice with anti-IL23(p19) showed this effect – 
intervention early in disease progression in NOD mice can significantly influence pathogenesis. 
We recognize that using NOD mice permits the manipulation of a target or pathways earlier in 
the disease progression than would be possible in humans, as interventions in humans can only 
occur in most cases after the disease is diagnosed. However, identifying an effect at this early 
stage of disease progression in NOD mice suggests that additional studies to determine the effect 
at later stages of disease progression in NOD mice are warranted. Ultimately, our study provides 
proof of concept that direct analysis of human islets is valuable for identifying promising targets 
for effective putative therapeutic interventions in human T1D. Moreover, studies of human 
disease tissue can lead to the repurposing of developed drugs or biologicals thereby speeding 
progress toward effective human therapeutics for T1D. 
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Figure Legends 
Figure 1. Cluster analysis of RNA sequencing data from human tissue samples including 
human islets with T1D. Gene expression levels were compared for the five islet preparations 
(two T1D and three controls) and 16 background tissues from the Illumina Human Body Map 
(GEO accession GSE30611). Genes with expression of RPKM > 0.5 in at least one of the 
samples, and with potential pathogenic relevance, were considered for analysis. For each pair of 
samples, a Spearman correlation coefficient (SCC) was computed from the RPKM expression 
levels. The heatmap shows the clustering dendrograms inferred by employing (1 – SCC) as 
distance function and complete linkage as clustering function, showing both a tight cluster of the 
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five islet preparations against the background tissues on one hand and a tight cluster of the two 
T1D samples as compared to the three normoglycemic control samples. 
 
Figure 2. Ingenuity Pathway Analysis (IPA) for up-regulated genes in canonical pathways 
identified in short-duration T1D. 667 genes were considered up-regulated in the short duration 
T1D sample compared to the normoglycemic control donors. These genes were subjected to gene 
set enrichment analysis using the IPA database based on Benjamini-Hochberg corrected Fisher 
tests. The “canonical pathways” identified by IPA for the upregulated genes in short-duration 
T1D are displayed. The length of the blue bars indicates the significance of the association 
between the set of genes and the keyword, and is expressed as minus the logarithm of the 
probability that a random set of genes from the human genome would be associated with the 
same keyword. The straight orange line indicates a threshold of 0.05 (corresponding to a –log 
(B–H p-value) of 1.3 on the upper Y-axis). The orange dots for each pathway (connected with a 
line) indicate the ratio (lower Y-axis) between the number of genes observed in the data set and 
the total number of genes in the pathway (as annotated in IPA). 
 
Figure 3. Diabetes free survival of NOD mice treated with or without IL-23/p19 inhibitor. 
(A) Insulitis scoring for NOD mice 6 weeks of age treated with CNTO6163 to block IL23/p19 or 
isotype control. (B) NOD mice treated with CNTO6163 to block IL23/p19 showed significantly 
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reduced diabetes incidence compared with isotype control treated NOD mice of the same age (p 
= 0.034). 
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Table 1. Expression of selected genes in human donor islets from short-duration (SD) T1D, 
long-duration (LD) T1D and non-diabetic controls. Genes with expression of RPKM > 0.5 in 
at least one of the samples studied and with potential pathogenic relevance are shown. For key 
cytokines or other immune-relevant signaling molecules (e.g. IFNG, IL17A etc) values are 
shown even when below detection level at all samples. 
 
Gene Description SD-T1D LD-T1D Ctrl-median 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 3.864 5.586 4.192 
CCL5 chemokine (C-C motif) ligand 5 8.591 0.877 0.707 
CCR5 C-C motif chemokine receptor 5 0.175 0.103 0.103 
CD2 CD2 molecule 0 0.260 0.034 
CD4 CD4 molecule 0.625 0.290 3.473 
CD5 CD5 molecule 0 0.072 2.636 
CD6 CD6 molecule 0 0.359 0.660 
CD8A CD8a molecule 0.134 0.233 0.280 
CD14 CD14 molecule 12.542 2.371 58.727 
CD22 CD22 molecule 0.505 0 4.567 
CD68 CD68 molecule 475.127 155.884 216.451 
CD86 CD86 molecule 1.631 0.162 0.537 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 22.271 15.710 9.911 
CLEC5A ENSG00000258227 0.108 0.273 0.372 
CSF2RB 
colony stimulating factor 2 receptor, 
beta, low-affinity (granulocyte-
macrophage) 
2.536 0.134 0.908 
CSF3 colony stimulating factor 3 (granulocyte) 253.810 1.265 2.582 
CTSB cathepsin B 203.303 163.176 433.834 
CTSH cathepsin H 42.622 165.632 52.752 
CXCL1 
chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
1379.470 67.349 152.284 
CXCL2 chemokine (C-X-C motif) ligand 2 443.036 84.223 90.415 
CXCL3 chemokine (C-X-C motif) ligand 3 164.310 13.695 15.896 
CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 373.120 92.100 18.942 
CXCL9 chemokine (C-X-C motif) ligand 9 0.214 0.031 0.023 
CXCL10 chemokine (C-X-C motif) ligand 10 0.443 0.241 0.075 
EBF1 early B-cell factor 1 1.181 0.264 1.088 
EMR2 egf-like module containing, mucin-like, hormone receptor-like 2 1.090 0.342 0.417 
FCGRT Fc fragment of IgG, receptor, transporter, alpha 42.974 42.853 90.638 
GATA3 GATA binding protein 3 0 0 0.042 
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GCG glucagon 196.361 60.420 18569.737 
GHRL ghrelin/obestatin prepropeptide 39.498 0.663 45.921 
IFNG interferon, gamma 0 0 0 
IL1B interleukin 1, beta 99.324 14.839 3.711 
IL1R2 interleukin 1 receptor, type II 3.170 1.178 2.413 
IL4 interleukin 4 0.000 0.000 0.085 
IL6 interleukin 6 (interferon, beta 2) 419.539 10.030 20.231 
IL10 interleukin 10 0.290 0.167 0.351 
IL13 interleukin 13 0 0 0 
IL17A interleukin 17A 0 0 0 
IL22 interleukin 22 0 0 0 
IL23A interleukin 23, alpha subunit p19 9.247 2.952 2.227 
INS Insulin 30.666 34.233 37139.093 
IRF4 interferon regulatory factor 4 0.170 0.039 0.126 
IRF8 interferon regulatory factor 8 1.558 1.570 1.786 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 0.851 0.617 1.042 
LEF1 lymphoid enhancer-binding factor 1 0.260 0.183 1.952 
MAFA v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (avian) 0.056 0.045 23.145 
NEUROD1 neurogenic differentiation 1 1.326 0.433 55.895 
NOS2 nitric oxide synthase 2, inducible 0.740 0.018 0.061 
PDX1 pancreatic and duodenal homeobox 1 3.868 5.505 10.587 
PPY pancreatic polypeptide 313.624 568.925 1951.846 
RORC RAR-related orphan receptor C 13.493 17.514 17.570 
RPL27A ribosomal protein L27a 3333.759 4380.496 2539.817 
RUNX2 runt-related transcription factor 2 0.402 0.176 1.558 
SATB1 SATB homeobox 1 13.673 12.280 13.465 
SOD2 superoxide dismutase 2, mitochondrial 6691.718 1580.293 329.756 
SST somatostatin 340.294 25.130 3513.745 
STAT4 signal transducer and activator of transcription 4 1.420 2.304 4.716 
TCF7 transcription factor 7 (T-cell specific, HMG-box) 9.229 4.477 6.849 
ZAP70 zeta-chain (TCR) associated protein kinase 70kDa 0 0.339 0 
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Table 2. Up- and down-regulated pathways identified in short- and long-duration T1D 
islets. Lists are restricted to Top 10 pathways identified for each group. The complete list for 
each group with additional detail can be found in the Supplemental Materials. The Benjamini-
Hochberg adjusted p-value for the significance (-Log10 (B-H p-value) used a cutoff of 1.3, 
which corresponds to > –log10(B-H p-value= 0.05). The ratio refers to the number of genes in 
the dataset compared to the total number of genes in the corresponding pathway.  
 
Up-regulated Pathways: Short-duration T1D  -log(B-H p-value) Ratio 
Granulocyte Adhesion and Diapedesis 18.3 0.203 
Agranulocyte Adhesion and Diapedesis 13.9 0.169 
LXR/RXR Activation 8.89 0.174 
Role of Macrophages, Fibroblasts and Endothelial Cells in RA 8.14 0.104 
Role of Cytokines in Mediating Communication between 
Immune Cells 8.08 0.259 
Communication between Innate and Adaptive Immune Cells 7.89 0.191 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 7.88 0.189 
Role of IL-17A in Psoriasis 7.82 0.615 
Atherosclerosis Signaling 7.24 0.15 
Graft-versus-Host Disease Signaling 6.84 0.25 
   
Up-regulated Pathways: Long-duration T1D   
γ-glutamyl Cycle 2.56 0.312 
Xenobiotic Metabolism Signaling 2.56 0.0662 
Acute Phase Response Signaling 2.56 0.0828 
Glutathione-mediated Detoxification 2.5 0.207 
FXR/RXR Activation 2.2 0.0873 
Eicosanoid Signaling 2.2 0.119 
LPS/IL-1 Mediated Inhibition of RXR Function 2.2 0.0676 
Complement System 2.17 0.162 
Leukotriene Biosynthesis 2.08 0.286 
Aryl Hydrocarbon Receptor Signaling 2 0.0786 
   
Down-regulated Pathways: Short-duration T1D   
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells 3.87 0.271 
Cardiac β-adrenergic Signaling 3.24 0.212 
GPCR-Mediated Integration of Enteroendocrine Signaling  2.54 0.25 
Axonal Guidance Signaling 2.42 0.14 
Cellular Effects of Sildenafil (Viagra) 2.27 0.192 
Dopamine-DARPP32 Feedback in cAMP Signaling 2.27 0.179 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Signaling by Rho Family GTPases 2.26 0.158 
Breast Cancer Regulation by Stathmin1 2.08 0.163 
CDK5 Signaling 2.08 0.202 
Maturity Onset Diabetes of Young (MODY) Signaling 2.08 0.381 
   
Down-regulated Pathways: Long-duration T1D    
Axonal Guidance Signaling 3.25 0.156 
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells 3.25 0.259 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.95 0.191 
LXR/RXR Activation 2.83 0.215 
GPCR-Mediated Integration of Enteroendocrine Signaling  2.53 0.25 
Neuropathic Pain Signaling In Dorsal Horn Neurons 2.53 0.211 
Cardiac β-adrenergic Signaling 2.53 0.197 
G-Protein Coupled Receptor Signaling 1.99 0.154 
Regulation of the Epithelial-Mesenchymal Transition Pathway 1.99 0.169 
Th2 Pathway 1.99 0.18 
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